MacuHealth and M&S Technologies Enter Partnership to Advance Patient Care and Treatment Protocols

LAS VEGAS, Sept. 6, 2017 /PRNewswire/ -- M&S Technologies, Inc of Niles, IL and MacuHealth, LP of Birmingham, MI have entered into a cooperative marketing agreement. Working together, M&S and MacuHealth will educate and train eye care professionals (ECPs) on the direct relationship between enriching macular pigment with nutritional supplements and optimizing visual performance.  As more and more optometric practices move toward the medical model, the combined body of scientific and clinical evidence available through M&S technologies and MacuHealth's unique formulation will help advance the quality of patient care. 

M&S has developed a quick and accurate Letter Contrast Sensitivity Protocol using a single Sloan letter optotype at 20/100 at 6 CPD (cycles per degree).  The protocol begins at 20% contrast and the doctor will increase or decrease the contrast percentage according to patient responses (whether they answer correctly or incorrectly). Their contrast level is recorded and appears on the screen.

Contrast Sensitivity has been a part of M&S software for over 20 years.  No other technology offers more science, peer reviews, or validations than the Smart System 20/20. 

"Measuring contrast sensitivity as part of every comprehensive eye exam will enable eye care professionals to determine true visual performance that cannot be obtained when measuring visual acuity," says Joe Marino, Founder and CEO of M&S Technologies, Inc.  "Contrast measures the quality of vision, whereas visual acuity measures the quantitative aspect of vision. Contrast sensitivity is an advanced form of vision testing and when integrated as the standard of care in today's practices, it will enable ECPs to pinpoint the needs of their patients and evaluate the best course of action to achieve a better outcome."

After a thorough review of contrast sensitivity technologies, partnering with M&S Technologies was an easy decision for MacuHealth. M&S prides itself in offering vision testing systems that are peer reviewed and calibrated to ANSI and ISO specifications. Similarly, MacuHealth has a significant body of peer reviewed evidence to support its safety and efficacy. The two companies will support each other's technologies with a high level of integrity and eloquent synergy.

"There is now level 1 scientific evidence that demonstrates a direct correlation between rebuilding and enriching macular pigment with MacuHealth's triple carotenoid formulation in patients with healthy eyes (with best corrected Snellen visual acuity) and patients with macular disease (such as AMD and diabetic retinopathy) with improved contrast sensitivity," explained Frederic Jouhet, Founder and Managing Director of MacuHealth, LP. "We now know with 100% confidence that enriching macular pigment with MacuHealth with LMZ³ will improve visual performance (contrast) even when the patient has what is normally considered perfect vision."

M&S and MacuHealth will soon be launching cooperative programs together to help ECPs purchase M&S contrast sensitivity technology or upgrade existing M&S technology in their practices. These programs will combine the power of advanced vision testing with the power of better vision and macular health through supplementation with MacuHealth.

Visit us at VEW to learn more:

M&S Technologies - Booth MS11039

MacuHealth - Booth MS704

About M&S Technologies, Inc:
Founded in 1990, M&S Technologies is a software company specializing in visual testing systems and dedicated to developing the very best products for eye-care professionals, optometry schools and universities, and products used in clinical trials. To date, over 27,000 systems are in use across 39 countries with a strong network that includes 25 distributors and several strategic industry alliances. Our hallmarks are always superior service and industry-leading technology and products that have been peer reviewed and calibrated to the ANSI and ISO specifications.

About MacuHealth, LP:

Founded in 2006, MacuHealth® with LMZ³ formula contains 10 mg of Lutein, 2 mg of Zeaxanthin and 10 mg of the most potent antioxidant in the macula, Meso-Zeaxanthin. MacuHealth takes immense pride in having helped to pioneer much of the revolutionary research behind critical carotenoid, Meso-Zeaxanthin and its role in preserving and improving visual function. More recently, the company has been supporting the emerging research on the fascinating correlation between carotenoid levels, impaired vision and cognitive performance. With over 30 peer reviewed publications that demonstrate the formula's efficacy, bioavailability and safety, plus a passion for protecting eyesight, MacuHealth® is at the forefront of preventative treatments for macular disease. The company holds both worldwide exclusivity and a patent on the science-based 10-10-2 formulation. With help from its distribution groups, MacuHealth in North America and Alliance Pharma in Europe, it has become the supplement of choice in the fight against AMD and enhancement of visual function worldwide.

SOURCE MacuHealth, LP

Related Links

http://www.macuhealth.com